Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | BMPR1B | O00238 | 4/20 | 0.32 |
| ▸ | BMPR1A | P36894 | 4/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22757285 | 0.88 | PTGS2 (0.36) | PTGS2SIGMAR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL21476163 | 0.86 | PTGS2 (0.40) | PTGS2PTGDR2BMPR1BBMPR1AACVRL1 | |
| SCHEMBL21476166 | 0.83 | SIGMAR1 (0.35) | PTGS2SIGMAR1 | |
| SCHEMBL21484161 | 0.82 | PTGS2 (0.35) | PTGS2SIGMAR1PTGDR2MAOAMAOB | |
| SCHEMBL21475878 | 0.82 | HRH3 (0.44) | PTGS2PTGDR2 | |
| SCHEMBL21484163 | 0.81 | SIGMAR1 (0.33) | PTGS2SIGMAR1 | |
| SCHEMBL21476001 | 0.80 | KCNH2 (0.38) | SIGMAR1BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL21476009 | 0.77 | BPTF (0.39) | PTGS2SIGMAR1PTGDR2ADORA2AADORA1 | |
| SCHEMBL1106511 | 0.72 | HRH3 (0.41) | PTGS2PTGDR2BMPR1BBMPR1AACVRL1 | |
| SCHEMBL21476161 | 0.70 | PTGS2 (0.36) | PTGS2PTGDR2BMPR1BBMPR1AACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | ITGB7, ITGB4, ITGA4 | PTGS2 4519/4885SIGMAR1 1331/4885PTGDR2 1564/4885 |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | PTGS2 4366/4885SIGMAR1 1104/4885PTGDR2 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.